In conclusion, a series of 3-arylbenzofuranone derivatives were designed, synthesised, and evaluated as multi-targeting anti-AD agents, which have inhibitory activity against ChEs and MAO-B and antioxidant activity. The gene discussed is MAOB; the disease is Alzheimer disease.